Pfizer (NYSE:PFE) will pay up to $250M to settle more than 10,000 U.S. lawsuits alleging that the company concealed cancer ...
The FDA pulled Zantac and its generic versions off the market after a cancer-causing substance called NDMA was found in ...
Pfizer has agreed to settle more than 10,000 lawsuits about cancer risks related to the now discontinued heartburn drug ...
In a bid to settle thousands of lawsuits over its discontinued heartburn drug Zantac, Pfizer Inc. (NYSE:PFE) has agreed to ...
The drugmaker was set to pay between $200 million and $250 million in the settlement, the newspaper reported, citing two ...
Pfizer has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, ...
Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug, ...
Pharmaceutical company, Pfizer Inc. has agreed to settle more than 10,000 cases accusing the company of hiding the cancer ...
Financial terms of the settlements were not immediately disclosed for the discontinued over-the-counter drug that was used to ...
Pfizer Inc. has agreed to settle more than 10,000 cases accusing it of hiding the cancer risks of its Zantac heartburn drug.
Benzinga - by Vandana Singh, Benzinga Editor. Pfizer Inc (NYSE:PFE) has reportedly settled 10,000 lawsuits alleging it concealed the cancer risks associated with its Zantac heartburn medication, ...
Pfizer has agreed offer payment of up to $250 million to settle more than 10,000 lawsuits in the United States over cancer risks associated with its now-discontinued heartburn drug Zantac, the ...